- BNF:
- 8.1.5
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- July 2017
Comments
DO NOT PRESCRIBE (DNP)6: NICE TA489 - vismodegib for treating basal cell carcinoma. (Decision date - December 2017)
RED1,2,3: For the treatment of adults with either Gorlin syndrome or non-Gorlin syndrome related multiple basal cell carcinomas. (Decision date - December 2021)
NHS England drug - to be used in line with NHS England commissioning intentions.
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again
